Genentech to study atezolizumab with Immune's CMB305 in soft tissue sarcoma; terminated
Executive Summary
Immune Design Corp. will bring together its CMB305 with Genentech Inc.'s atezolizumab in a randomized Phase II trial that will test the safety and efficacy of the combination in soft tissue sarcoma.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Terminated
Deal Type
-
Alliance
- Intra-Biotech Deal
- Trial Collaborations
- R&D (No Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice